Arcalesy binds to IL-1 beta and to a lesser extent IL-1 alpha thus preventing their interactions with inflammatory cell surface receptors. This reduces the inflammatory response that results from under-production of the protein Cryopyrin due to a mutation in the NLRP-3 gene. Cryopyrin down-regulates production of IL-1.

**Pre-Authorization Criteria:** Cryopyrin-associated periodic syndromes (e.g. familial cold autoinflammatory syndrome; Muckle-Wells syndrome) in adults and children 12 years and older

**Dosing: Adult**

*Cryopyrin-associated periodic syndromes:* SubQ: Loading dose 320 mg given as 2 separate injections (160 mg each) on the same day at 2 different sites, followed by a once-weekly dose of 160 mg.

**Note:** Do not administer more frequently than once weekly.

**Dosing: Pediatric**

*Cryopyrin-associated periodic syndromes:* Children ≥12 years: SubQ: Loading dose 4.4 mg/kg (maximum dose: 320 mg) given as 1-2 separate injections (maximum: 2 mL/injection; administer at 2 different sites if multiple injections are necessary) on the same day, followed by a once-weekly dose of 2.2 mg/kg (maximum dose: 160 mg).

**Note:** Do not administer more frequently than once weekly.

**PRECAUTIONS:**

- predisposition to infection; may increase total cholesterol, HDL, LDL and triglycerides; patients should be brought up to date with all immunizations; live vaccines should not be given concurrently

**DRUG INTERACTIONS:** increased risk of infection if used with TNF-antagonists; enhanced immunosuppression
and/or side effects if used with other immunosuppressants; see product information for other drug interactions

REFERENCES

Revision History:
Date Approved by P&T Committee: 10/22/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD Date Approved by P&T Committee: 1/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 9/30/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>